[ Price : $8.95]
FDA announces a 4/12 Nonprescription Drugs Advisory Committee meeting to discuss the adequacy of efficacy data available for over-...[ Price : $8.95]
An unfavorable interim analysis leads Incyte to discontinue the Phase 3 LIMBER-304 myelofibrosis trial due to efficacy concerns.[ Price : $8.95]
Federal Register notice: FDA announces a 4/20 Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committe...[ Price : $8.95]
Federal Register notice: FDA provides notice that is has received a copy of a patent infringement complaint that had been filed ag...[ Price : $8.95]
FDA clears an Abbott 510(k) for its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensor...[ Price : $8.95]
CDER director Patrizia Cavazzoni says the agency is stepping up its actions to prevent contaminated drug products, including cough...[ Price : $8.95]
Presumably in an attempt to block or delay potential generic Mayzent products, Novartis petitions FDA to make generic versions mee...[ Price : $8.95]
Exelixis says its Phase 3 CONTACT-03 study evaluating the companys Cabometyx (cabozantinib) in combination with atezolizumab versu...